Last $127.67 USD
Change Today +0.88 / 0.69%
Volume 634.3K
TMO On Other Exchanges
New York
As of 8:04 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

thermo fisher scientific inc (TMO) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - $129.77
52 Week Low
10/15/14 - $107.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

thermo fisher scientific inc (TMO) Details

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. It operates in three segments: Analytical Technologies; Specialty Diagnostics; and Laboratory Products and Services. The Analytical Technologies segment offers instruments, reagents, consumables, software, and services for applications in the laboratory, on the production line, and in the field. It serves pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as the clinical laboratory. The Specialty Diagnostics segment provides various diagnostic test kits, reagents, culture media, instruments, and associated products for customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. This segment offers blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, calibrators, controls, and calibration verification fluids; human leukocyte antigen typing and testing for the organ transplant; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; and products for cancer diagnosis and medical research in histology, cytology, and hematology applications. The Laboratory Products and Services segment offers sample preparation and preservation equipment, cold storage equipment, centrifugation products, biological safety cabinets, temperature control products, water analysis instruments, and other laboratory equipment, as well as laboratory consumables, research and safety market solutions, and biopharma services. The company has a strategic collaboration with Samsung Electronics Co. Ltd. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

50,000 Employees
Last Reported Date: 02/27/14
Founded in 1956

thermo fisher scientific inc (TMO) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $653.7K
Executive Vice President and President of Lab...
Total Annual Compensation: $697.9K
Senior Vice President and President of Analyt...
Total Annual Compensation: $514.1K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $622.6K
Compensation as of Fiscal Year 2013.

thermo fisher scientific inc (TMO) Key Developments

Thermo Fisher and Samsung Electronics Form Strategic Collaboration

Thermo Fisher Scientific, Inc., and Samsung Electronics Co. Ltd. have formed a strategic collaboration. The companies will jointly design, develop and market new POC solutions in key applications, such as the detection of sepsis, drugs of abuse and therapeutic drug monitoring as well as the detection of cardiac problems and women's health conditions.

Thermo Fisher Scientific, Inc. Launches Lipofectamine MessengerMAX

Thermo Fisher Scientific Inc. has launched Lipofectamine MessengerMAX, a new transfection reagent for mRNA delivery in neurons and primary cell types. Lipofectamine MessengerMAX offers up to a five times the efficiency of DNA reagents and enables researchers to easily transfect biologically relevant cell models without electroporation or viruses. DNA reagents tend to be inefficient for transfection of primary cells, and other approaches can introduce toxicity into cells and negatively affect data. Primary cell models such as neurons, hepatocytes, keratinocytes and fibroblasts provide researchers with more meaningful answers to their research questions. To transfect these cells, Lipofectamine MessengerMAX uses novel lipid nanoparticle technology optimized to deliver the amount of mRNA possible without the need to enter the nucleus. MessengerMax is the newest high-efficiency transfection reagent in Thermo Fisher's portfolio since introducing Lipofectamine 3000 in January.

Thermo Fisher Scientific Inc. Prices Offering of EUR 640 Million 2.000% Senior Notes Due 2025

Thermo Fisher Scientific Inc. announced that it has priced its previously announced offering of EUR 640 million aggregate principal amount of 2.000% senior notes due 2025 at an issue price of 99.680% of the principal amount. The issuance of the notes is expected to close on or about November 24, 2014, subject to customary closing conditions. The notes will pay interest on an annual basis. Thermo Fisher plans to use the net proceeds of the offering principally to repay approximately $70 million of short-term indebtedness, which consists of commercial paper, and to repay approximately $600 million of long-term indebtedness, which consists of amounts outstanding under $5.0 billion term loan. The joint book-running managers for the offering are HSBC Bank plc, Deutsche Bank Securities, Inc., and RBS Securities Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TMO:US $127.67 USD +0.88

TMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.85 USD +0.15
Corning Inc $23.32 USD +0.10
Danaher Corp $86.73 USD -0.06
General Dynamics Corp $141.39 USD -0.15
Safran SA €50.64 EUR -0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation TMO Industry Range
Price/Earnings 30.8x
Price/Sales 3.2x
Price/Book 2.5x
Price/Cash Flow 31.2x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERMO FISHER SCIENTIFIC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at